169.85
price up icon1.55%   2.60
after-market Dopo l'orario di chiusura: 169.46 -0.39 -0.23%
loading

Belite Bio Inc Adr Borsa (BLTE) Ultime notizie

pulisher
Apr 04, 2026

Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - Defense World

Apr 04, 2026
pulisher
Apr 03, 2026

Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - tipranks.com

Apr 03, 2026
pulisher
Apr 03, 2026

Belite Bio (BLTE) Is Up 7.9% After Phase 3 DRAGON Win And $402M OfferingHas The Bull Case Changed? - Sahm

Apr 03, 2026
pulisher
Apr 03, 2026

Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com

Apr 03, 2026
pulisher
Apr 02, 2026

[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Belite Bio (BLTE) CFO now holds 289,736 vested option shares - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Belite Bio (BLTE) CSO gains 144,868-share option vesting - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Belite Bio Jumps on Drug Hopes and Analyst Boost - TipRanks

Apr 02, 2026
pulisher
Apr 01, 2026

Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - TipRanks

Apr 01, 2026
pulisher
Mar 31, 2026

Belite Bio, Inc. ADR Shares Surge on Drug Progress - TipRanks

Mar 31, 2026
pulisher
Mar 31, 2026

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - The Manila Times

Mar 31, 2026
pulisher
Mar 31, 2026

Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Belite Bio (BLTE) 2025 20-F: Tinlarebant NDA plan and rising losses - stocktitan.net

Mar 31, 2026
pulisher
Mar 30, 2026

Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - Barchart.com

Mar 30, 2026
pulisher
Mar 30, 2026

Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat

Mar 30, 2026
pulisher
Mar 28, 2026

(BLTE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 28, 2026
pulisher
Mar 21, 2026

Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 21, 2026
pulisher
Mar 18, 2026

Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan

Mar 18, 2026
pulisher
Mar 17, 2026

(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 17, 2026
pulisher
Mar 17, 2026

Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks

Mar 17, 2026
pulisher
Mar 17, 2026

Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat

Mar 17, 2026
pulisher
Mar 12, 2026

Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World

Mar 12, 2026
pulisher
Mar 12, 2026

Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria

Mar 12, 2026
pulisher
Mar 12, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 12, 2026
pulisher
Mar 11, 2026

H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria

Mar 11, 2026
pulisher
Mar 10, 2026

Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks

Mar 10, 2026
pulisher
Mar 09, 2026

Belite Bio at Leerink Conference: Tinlarebant’s Promising Trials - Investing.com

Mar 09, 2026
pulisher
Mar 09, 2026

Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat

Mar 09, 2026
pulisher
Mar 07, 2026

What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World

Mar 07, 2026
pulisher
Mar 06, 2026

(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 06, 2026
pulisher
Mar 06, 2026

Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat

Mar 06, 2026
pulisher
Mar 04, 2026

Belite Bio Q4 Earnings Call Highlights - Defense World

Mar 04, 2026
pulisher
Mar 04, 2026

Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World

Mar 04, 2026
pulisher
Mar 04, 2026

Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - Defense World

Mar 04, 2026
pulisher
Mar 03, 2026

Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail

Mar 03, 2026
pulisher
Mar 03, 2026

Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com Canada

Mar 03, 2026
pulisher
Mar 03, 2026

Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook By Investing.com - Investing.com South Africa

Mar 03, 2026
pulisher
Mar 03, 2026

Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com Nigeria

Mar 03, 2026
$99.12
price up icon 0.49%
$28.33
price up icon 1.76%
$48.57
price up icon 0.16%
$91.18
price up icon 1.97%
ONC ONC
$310.79
price up icon 0.76%
$162.43
price down icon 1.47%
Capitalizzazione:     |  Volume (24 ore):